VC Fund Dossiers

Artha delivers serious numbers - 61% IRR significantly outperforming the 35% industry average for microVCs, with DPI approaching 20%. Anirudh gets his hands dirty - he literally mystery shops portfolio companies like OYO, booking stays himself to ensure quality. He's refreshingly blunt about 'tourist founders' who started companies just because capital was easy, calling the current funding squeeze a necessary correction. The 'winners-only' Select Fund strategy is smart - doubling down on proven portfolio companies rather than constantly sourcing new deals. The portfolio employs 20,000+ people directly and 100,000+ indirectly, showing real scale and impact beyond just paper valuations.

Look, Fearless Fund just survived one of the biggest legal battles in modern VC—they settled with Edward Blum's anti-DEI crusade in September 2024, shutting down their grant program but keeping the core VC operations intact. The personal toll was brutal: Simone received death threats, corporate sponsors dropped from 20 to just 3 (UPS, JPMorgan, Costco), and co-founder Ayana Parsons stepped down in June 2024. But here's the thing—they're not backing down. They launched the Fearless Global Initiative, expanded to Africa, and are still cutting million-dollar checks to WOC founders. The settlement actually shows their resilience and strategic thinking—they avoided a Supreme Court case that could have nuked DEI investing nationwide.

Social Starts has been around the block since 2012 and claims to be "uniquely data-driven" - though honestly, every VC says that these days. What's actually interesting is their founder William Lohse's track record - the guy was an early Pinterest investor and has been doing this since the 1990s, which gives them real pattern recognition. They've been named the top fund under $100M since 2013 and were the fifth most active early stage fund worldwide in 2015, suggesting they actually move fast and deploy capital. The health and happiness thesis sounds a bit fluffy, but their portfolio shows they're willing to bet on everything from AI diagnostics to alternative proteins. They focus investments in 4-5 key areas that change every six months as they evaluate market shifts, and their early investing locks in pro rata for Series A - so they're not one-and-done investors.